Predictive Stock Analysis

POAI -  USA Stock  

USD 1.00  0.12  10.71%

The current Predictive Oncology price drop may encourage stockholders to take a closer look at the company as it is trading at a share price of 1.0 on 8,732,078 in trading volume. The company directors and management were unable to exploit market volatilities in May. However, diversifying your overall positions with Predictive Oncology can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.85. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Predictive Oncology partners.
Please check Your Equity Center.

Search Stock Analysis 

 
Refresh
The Predictive Oncology stock analysis report makes it easy to digest most publicly released information about Predictive Oncology and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Predictive stock analysis module also helps to analyze the Predictive Oncology price relationship with some important fundamental indicators such as market cap and management efficiency.

Predictive Stock Analysis Notes

The company recorded a loss per share of 2.21. Predictive Oncology had not issued any dividends in recent years. The entity had 1-10 split on the 29th of October 2019. Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. Predictive Oncology operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 22 people. To find out more about Predictive Oncology contact the company at 651 389 4800 or learn more at http://www.predictive-oncology.com.

Predictive Oncology Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Predictive Oncology's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Predictive Oncology or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Predictive Oncology generates negative expected return over the last 90 days
Predictive Oncology has high historical volatility and very poor performance
Predictive Oncology has some characteristics of a very speculative penny stock
The company currently holds 5.87 M in liabilities with Debt to Equity (D/E) ratio of 2.22, implying the company greatly relies on financing operations through barrowing. Predictive Oncology has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations when due.
The entity reported the previous year's revenue of 1.25 M. Net Loss for the year was (26.44 M) with profit before overhead, payroll, taxes, and interest of 805.08 K.
Predictive Oncology currently holds about 678.33 K in cash with (12.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Latest headline from www.equities.com: Predictive Oncology Inc falls -7.2070 percent for June 15 - Equities.com

Predictive Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 50.26 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Predictive Oncology's market, we take the total number of its shares issued and multiply it by Predictive Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (44.03) % which means that it has lost $44.03 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (373.14) %, meaning that it created substantial loss on money invested by shareholders. Predictive Oncology management efficiency ratios could be used to measure how well predictive oncology manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 17th of June 2021, Predictive Oncology holds the risk adjusted performance of (0.013548), and Coefficient Of Variation of (2,751). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Predictive Oncology, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Predictive Oncology, which can be compared to its competitors. Please check Predictive Oncology variance, as well as the relationship between the maximum drawdown and semi variance to decide if Predictive Oncology is priced some-what accurately, providing market reflects its current price of 1.0 per share. Given that Predictive Oncology is a hitting penny stock territory we advise to closely look at its total risk alpha.

Predictive Oncology Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Predictive Oncology more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Predictive Oncology Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Predictive Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Predictive Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Predictive Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jenkins Christina Lee Md over a month ago via Macroaxis 
Acquisition by Jenkins Christina Lee Md of 5000 shares of Predictive Oncology subject to Rule 16b-3
St Clair Gregory Sr over two months ago via Macroaxis 
Acquisition by St Clair Gregory Sr of 6887 shares of Predictive Oncology subject to Rule 16b-3
Schwartz Carl I over two months ago via Macroaxis 
Acquisition by Schwartz Carl I of 100401 shares of Predictive Oncology subject to Rule 16b-3
Schwartz Carl I over three months ago via Macroaxis 
Acquisition or disposition of Predictive Oncology securities by Schwartz Carl I
St Clair Gregory Sr over three months ago via Macroaxis 
Acquisition by St Clair Gregory Sr of 20481 shares of Predictive Oncology subject to Rule 16b-3
Schwartz Carl I over six months ago via Macroaxis 
Sale by Schwartz Carl I of 640 shares of Predictive Oncology
St Clair Gregory Sr over six months ago via Macroaxis 
Acquisition by St Clair Gregory Sr of 6142 shares of Predictive Oncology subject to Rule 16b-3
Schwartz Carl I over six months ago via Macroaxis 
Acquisition by Schwartz Carl I of 300000 shares of Predictive Oncology subject to Rule 16b-3
Schwartz Carl I over six months ago via Macroaxis 
Acquisition by Schwartz Carl I of 6050 shares of Predictive Oncology subject to Rule 16b-3
Gabriel Richard L over six months ago via Macroaxis 
Purchase by Gabriel Richard L of 4000 shares of Predictive Oncology
Gabriel Richard L over six months ago via Macroaxis 
Purchase by Gabriel Richard L of 2610 shares of Predictive Oncology
St Clair Gregory Sr over six months ago via Macroaxis 
Acquisition by St Clair Gregory Sr of 4698 shares of Predictive Oncology subject to Rule 16b-3

Predictive Oncology Predictive Daily Indicators

Predictive Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Predictive Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Predictive Oncology Forecast Models

Predictive Oncology time-series forecasting models is one of many Predictive Oncology's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Predictive Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Predictive Oncology Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Predictive Oncology stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Predictive shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Predictive Oncology. By using and applying Predictive Stock analysis, traders can create a robust methodology for identifying Predictive entry and exit points for their positions.
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. Predictive Oncology operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Predictive Oncology to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Crypto Correlations Now

   

Crypto Correlations

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
All  Next Launch Module
Please check Your Equity Center. Note that the Predictive Oncology information on this page should be used as a complementary analysis to other Predictive Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Predictive Oncology Stock analysis

When running Predictive Oncology stock analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's stock examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.
CEO Directory
Screen CEOs from public companies around the world
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
ETF Directory
Find actively-traded Exchange Traded Funds (ETF) from around the world
Go
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology stock's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's stock value and its price as these two are different measures arrived at by different means. Investors typically determine Predictive Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.